Custom Search
ADVERTISEMENT
Today's Health Headlines
(Reuters Health) - Pregnant women should get their blood pressure checked at each prenatal visit to screen for preeclampsia, a potentially fatal complication that can damage the kidneys, liver, eyes and brain, new U.S. guidelines say.

WASHINGTON (Reuters) - The U.S. government's costs could increase by $2.3 billion in 2018 if Congress and President Donald Trump decide not to fund Obamacare-related payments to health insurers, according to a study released Tuesday by the Kaiser Family Foundation.

(Reuters Health) - People who wait up to nine months to get a colonoscopy after fecal tests show potential tumors are no more likely to be diagnosed with cancer or advanced malignancies than those who get follow-up colonoscopies sooner, a U.S. study suggests.

(Reuters) - A bill expected this week in the U.S. House of Representatives would weaken a Food and Drug Administration rule governing e-cigarettes and represent a major victory for the $4.4 billion U.S. vaping industry.

(Reuters Health) - While most doctors think patients prefer not to disclose their sexual orientation, a new survey found people are willing to provide the information when asked.

(Reuters Health) - Transgender preschoolers are no less confident than their peers about their gender, a new study found.

LONDON, April 25 (Reuters) - Scientists in the United States have developed a fluid-filled womb-like bag known as an extra-uterine support device that could transform care for extremely premature babies, significantly improving chances of survival.

Can playground design help reduce bullying?
Tue, 25 Apr 2017 15:45:41 -0400
(Reuters Health) - Playgrounds designed with risk-taking in mind may mean more pushing and shoving during recess, but they also might make kids less likely to feel bullied, a small experiment in New Zealand suggests.

STOCKHOLM (Reuters) - An outbreak of H5N8 bird flu has been detected at a hen farm near the town of Nykoping in eastern Sweden, the country's board of agriculture said on Tuesday.

ZURICH (Reuters) - Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease.

ADVERTISEMENT
Make OUR Portal, YOUR Portal
Username: 
Password:
 Remember Remember me 
Not a Customer? Click here!
Browse RSS Feeds
click here when finished
Save Page Layout
Video
loading